210 results
Page 2 of 11
6-K
EX-99.1
hyw0eiwau3w 7wc30z
20 Jun 23
Current report (foreign)
5:53pm
6-K
EX-99.1
4azol3jt
1 May 23
Current report (foreign)
8:00am
6-K
EX-99.1
n2kq9f2nyr ag4
30 Nov 22
Current report (foreign)
9:08pm
6-K
EX-99.2
lets94
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.1
g1j8tlzgz hd94
7 Oct 22
Notice of Annual General Meeting
3:06pm
6-K
EX-99.1
abtfxocjhr0 pc
14 Sep 22
Current report (foreign)
10:31am
6-K
EX-99.2
uh0yrgysq9
29 Aug 22
Current report (foreign)
4:00pm
424B5
4ir9l6yil wdk8vziebt
19 Aug 22
Prospectus supplement for primary offering
10:52am
6-K
EX-99.1
qlb2kq0q
1 Aug 22
Current report (foreign)
4:48pm
6-K
osvvu9
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
5qdqs4o1 9q
8 Jul 22
Current report (foreign)
8:58am
6-K
EX-99.2
awnmw zzaiz
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
x12tyt78nuy z1
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.1
33u9c
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
EX-99.1
1sekh kalnfp9h3xi563
31 Mar 22
Portage Biotech Provides Update on Clinical-Stage and Development Programs
8:00am